Compound details
4-hydroxy-3-methyl-5-(2-phenylethyl)-2,5-dihydrofuran-2-one
| Compound ID | CDAMM00073 |
|---|---|
| Common name | 4-hydroxy-3-methyl-5-(2-phenylethyl)-2,5-dihydrofuran-2-one | IUPAC name | 3-hydroxy-4-methyl-2-(2-phenylethyl)-2H-furan-5-one |
| Molecular formula | C13H14O3 |
| Retention time | 41.34 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 219.102 | Theoretical mz | 219.102 |
| Error | 1.5 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.8868 |
| Inchi key | HVEBVQQBKOIZHU-UHFFFAOYSA-N |
|---|---|
| Smiles | CC1=C(C(OC1=O)CCC2=CC=CC=C2)O |
| Superclass | Organoheterocyclic compounds |
| Class | Dihydrofurans |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| Q16853 | AOC3 | Amine oxidase, copper containing | T69619 | SEA |
| P15144 | ANPEP | Aminopeptidase N | T67272 | SEA |
| Q96RJ0 | TAAR1 | Trace amine-associated receptor 1 (by homology) | T99524 | SEA |
| Q05940 | SLC18A2 | Synaptic vesicular amine transporter (by homology) | T48873 | SEA |
| Q14832 | GRM3 | Metabotropic glutamate receptor 3 | T02719 | SEA |
| P15121 | AKR1B1 | Aldose reductase | T26623 | SEA |
| P23141 | CES1 | Acyl coenzyme A:cholesterol acyltransferase | T76369 | SEA |
| P14920 | DAO | D-amino-acid oxidase | T33124 | SEA |
| P62942 | FKBP1A | FK506-binding protein 1A | T76059 | SEA |
| P49286 | MTNR1B | Melatonin receptor 1B | T48268 | SEA |
| Q16548 | BCL2A1 | Bcl-2-related protein A1 (by homology) | T12797 | SEA |
| Q9NRA0 | SPHK2 | Sphingosine kinase 2 | T31989 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T69619 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | Q16853 | AOC3 |
| T67272 | DI0351 | Psoriasis | [ICD-11: EA90] | P15144 | ANPEP |
| T99524 | DI0040 | Attention deficit hyperactivity disorder | [ICD-11: 6A05] | Q96RJ0 | TAAR1 |
| T99524 | DI0149 | Focal/segmental autonomic disorder | [ICD-11: 8D8A] | Q96RJ0 | TAAR1 |
| T99524 | DI0290 | Narcolepsy | [ICD-11: 7A20] | Q96RJ0 | TAAR1 |
| T48873 | DI0079 | Choreiform disorder | [ICD-11: 8A01] | Q05940 | SLC18A2 |
| T48873 | DI0125 | Dissociative neurological symptom disorder | [ICD-11: 6B60] | Q05940 | SLC18A2 |
| T48873 | DI0129 | Dystonic disorder | [ICD-11: 8A02] | Q05940 | SLC18A2 |
| T48873 | DI0137 | Essential hypertension | [ICD-11: BA00] | Q05940 | SLC18A2 |
| T48873 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | Q05940 | SLC18A2 |
| T02719 | DI0370 | Schizophrenia | [ICD-11: 6A20] | Q14832 | GRM3 |
| T26623 | DI0298 | Neuropathy | [ICD-11: 8C0Z] | P15121 | AKR1B1 |
| T26623 | DI0366 | Rheumatoid arthritis | [ICD-11: FA20] | P15121 | AKR1B1 |
| T76369 | DI0335 | Peroxisomal disease | [ICD-11: 5C57] | P23141 | CES1 |
| T76369 | DI0398 | Synthesis disorder | [ICD-11: 5C52-5C59] | P23141 | CES1 |
| T33124 | DI0038 | Ataxic disorder | [ICD-11: 8A03] | P14920 | DAO |
| T33124 | DI0370 | Schizophrenia | [ICD-11: 6A20] | P14920 | DAO |
| T76059 | DI0331 | Parkinsonism | [ICD-11: 8A00] | P62942 | FKBP1A |
| T76059 | DI0349 | Pruritus | [ICD-11: EC90] | P62942 | FKBP1A |
| T76059 | DI0413 | Transplant rejection | [ICD-11: NE84] | P62942 | FKBP1A |
| T48268 | DI0214 | Insomnia | [ICD-11: 7A00-7A0Z] | P49286 | MTNR1B |
| T31989 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | Q9NRA0 | SPHK2 |